Finally, another piece of the puzzle emerges for suicide risk assessments

As the medical field has received technical innovation after technical innovation, psychiatry has been left with surprisingly litte. Now, with the EDOR-test, a new and objective method for assessing suicide risk in patients with a primary depression is available.

Take me to the product

What is hyporeactivity and the EDOR® test?

The EDOR test is based on analysing immediate and non- conscious electrodermal reactions to sound stimuli. Reaction patterns showing fast habituation are identified as hyporeactive, functioning as a marker for high risk of suicide and violent suicide attempts in patients with a primary depression.

Hyporeactivity as a suicide risk marker is stable over time, remains in remission and in later depression episodes. It is also independent from age, gender, symptoms of depression, severity or depth of depressive state and serotonin activity (5-HIAA in liquor).

How it can be used in clinical routine

Information provided by the test functions as an objective complement to the overall clinical interview and patient history. Combining information about patients with the EDOR Test provides a more complete basis for assessing suicide risk, a risk unknown to both patient and clinician.

EDOR Test information support assessing risk, and helps with:

  • Managing limited psychiatric care resources by allocating costly activities or care time to the right patients
  • Decisions on treatment plans tailored to the patients’ needs and situation over time
  • Patient and treatment team communication

What the test can mean for the patient

Irrespective of test result, experience from clinical use is that the information can help the patient and ensuring a feeling that patients are taken seriously at the clinic.

Patients tested as hyporeactive many times value the increased contact with the caregiver and can provide a relief from feelings of guilt. Also, it serves as an explanation to why some measures are needed. Patients with a normal reactivity can lower some of their and their relatives’ anxiety, focusing on healing from their depressive episode.

More about the EDOR Method

Latest news

Emotra undertecknar avsiktsförklaring med engelskt psykiatriskt sjukhus

November 16th, 2018|Kommentarer inaktiverade för Emotra undertecknar avsiktsförklaring med engelskt psykiatriskt sjukhus

Emotra meddelar att man tecknat ett så kallat ”Letter of Intent” med ett stort Londonbaserat psykiatrisjukhus. Avtalet ger sjukhuset rätt [...]

Se vår presentation från Stora Aktiedagen i Göteborg den 12 november

November 14th, 2018|Kommentarer inaktiverade för Se vår presentation från Stora Aktiedagen i Göteborg den 12 november

Under ”Stora Aktiedagen”, som arrangerades av Aktiespararna den 12 november i Göteborg, presenterades Emotra och EDOR®. Nedan återfinns en direktlänk [...]

Emotra: Framgångsrika möten med psykiatriska sjukhus

November 14th, 2018|Kommentarer inaktiverade för Emotra: Framgångsrika möten med psykiatriska sjukhus

Nyligen har Emotra genomfört ett antal möten med beslutsfattare som avser att gå vidare och prova EDOR® i rutinmässig användning. [...]

”Hemma hos Emotra”: Intervju med VD och styrelseordförande

November 12th, 2018|Kommentarer inaktiverade för ”Hemma hos Emotra”: Intervju med VD och styrelseordförande

I en nyligen inspelad ”HemmaHos-video”, intervjuas VD, Daniel Poté och styrelsens ordförande, Claes Holmberg om utvecklingen i Emotra.   181112 [...]